Araştırma Makalesi
PDF EndNote BibTex RIS Kaynak Göster

PANDEMİNİN ERKEN DÖNEMİNDE COVID-19 İÇİN POTANSİYEL TEDAVİ SEÇENEKLERİ: HIZLI SİSTEMATİK İNCELEME

Yıl 2020, Cilt 4, Sayı 2, 36 - 48, 31.12.2020

Öz

SARS-CoV-2 enfeksiyonununa karşı pandeminin erken döneminde, hastalığı tedavi edebilecek etkinliği bilimsel olarak kanıtlanmış bir tedavi bulunmamakla birlikte, tanı alan hastaların sağlık durumlarının ciddiyetine göre her ülkede farklı tedaviler uygulamaktadırlar. Bu çalışmada, COVID-19 pandemisinin erken döneminde teda-vide kullanılabilecek potansiyel tedavi seçenekleri üzerine yapılan bilimsel çalışmalar ile ilgili hızlı bir gözden geçirme yapılması amaçlanmıştır. Literatür taraması, OVID-MEDLINE, Web of Science ve Dergipark veri tabanlarında 01.01.2020-25.04.2020 tarih aralığını kapsayacak şekilde yapılmıştır. Tarama sonucunda top-lam 629 çalışmaya ulaşılmış ve değerlendirme sonrasında kalan 25 çalışma tam metin değerlendirmesine tabi tutulmuştur. Sonuç olarak; COVID-19 pandemisinin erken döneminde, hastalığın tedavisine yönelik etkinliği henüz bilimsel olarak kanıtlanmış bir tedavinin bulunmadığı, ancak farklı ilaçların potansiyel etkileri ile ilgili güçlü kanıtlar elde edebilmek için klinik çalışmaların halen devam ettiği ve mevcut ilaç seçeneklerine de potan-siyel yan etkiler açısından dikkatli yaklaşılması gerektiğinin vurgulandığı görülmüştür. Tedavide kullanılabile-cek ilaçların etkilerine ilişkin tartışmaların geniş çaplı klinik araştırmalardan gelecek kanıtlarla cevaplanabile-ceği düşünülmektedir.

Kaynakça

  • Ahn, DG., Shin, HJ., Kim, MH., Lee, S., Kim, HS., Myoung, J., Kim, BT., Kim, SJ. (2020). Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324. doi: 10.4014/jmb.2003.03011. PMID: 32238757
  • Arsene, AL., Ion-Bogdan Dumıtrescu, IB., Drăgoı CM., Udeanu, DI., Lupulıasa, D., Jınga 1V. ve diğ. (2020). A New Era for the Therapeutic Management of the Ongoing COVID-19 Pandemic FARMACIA Vol. 68, 2. https://www.researchgate.net/publication/341036236_A_new_era_for_the_therapeutic_management_of_the_ongoing_COVID-19_pandemic
  • Bebitoğlu, B., Oğuz, E., Hodzic,A., Hatiboğlu, N., Kam, Ö. (2020) Klorokin/Hidroksiklorokin: COVID-19 Tedavisi ile Gündeme Gelen Eski Bir İlaca Farmakolojik Bakış, Anadolu Kliniği Tıp Bilimleri Dergisi, Ocak 2020; Cilt 25, Özel Sayı https://dergipark.org.tr/tr/download/article-file/1115947
  • Borba, MGS. Va,. FFA. Sampaio, VS. Alexandre, MAA., Melo GC, Brito M. ve CloroCovid-19 Team (2020). Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857. PMID: 32330277.
  • Centers for Disease Control and Prevention (2020). Erişim: 18 Mayıs 2020 https://www.cdc.gov/coronavirus/COVID-19/index.html.
  • Chakraborty, C., Sharma, A.R.. Sharma, G, Bhattacharya, M., Lee, S.S.(2020). SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. European Review for Medical and Pharmacological Sciences 2020; 24: 4016-4026. https://pubmed.ncbi.nlm.nih.gov/32329877/
  • Demirbilek, Y., Pehlivantürk, G., Özgüler, ZÖ., Alp Meşe, E., (2020) COVID-19 outbreak control, example of ministry of health of Turkey Turk J Med Sci (2020) 50: 489-494 T https://dergipark.org.tr/tr/pub/tbtkmedical/issue/53865/724486ÜBİTAK doi:10.3906/sag-2004-187.
  • Dong, L., Hu, S., Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012. PMID: 32147628.
  • Dünya Sağlık Örgütü (2020). Erişim: 18 Mayıs 2020. Coronavirus disease (COVID-19) Erişim: 20 Mayıs 2020.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they happen
  • Esposito,S., Noviello, S., Pagliano, P. (2020). Update on treatment of COVID-19:ongoing studies between promising and disappointing results. Le Infezioni in Medicina, n. 2, 198-211, 2020. https://pubmed.ncbi.nlm.nih.gov/32335561/
  • Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020;20:105949. doi: 10.1016/j.ijantimicag. 2020.105949 https://pubmed.ncbi.nlm.nih.gov/32205204/
  • Gao, J.; Tian, Z.; Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends 2020, 14, 72–73) ( Wang, M.; Cao, R.; Zhang, L.; Yang, X.;
  • Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30, 269–271.
  • Gupta, N., Agrawal, S., ve Ish, P. (2020). Chloroquine in COVID-19: the evidence Monaldi Archives for Chest Disease. Monaldi Archives for Chest Disease, Vol. 90 No. 1 (2020) https://covid19.elsevierpure.com/en/publications/chloroquine-in-covid-19-the-evidence
  • Harapana, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Wagner, A. L., & Mudatsir, M. (2020). Coronavirus disease 2019 (COVID-19): A literature review. Journal of infection and public health, 13(5), 667–673. https://doi.org/10.1016/j.jiph.2020.03.019
  • Ingraham, NE., Boulware, D., Sparks, MA., Schacker, T., Benson, B., Sparks, JA. ve diğ. (2020). Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2. Critical Care (2020) 24:182. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187670/
  • Iyer M., Jayaramayya, K., Subramaniam, MD., Lee, SB., Dayem, AA., Cho, SG, Vellingiri, B. 82020). COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep. 2020 Apr;53(4):191-205. doi: 10.5483/BMBRep.2020.53.4.080. PMID: 32336317; PMCID: PMC7196187.
  • Jin, YH., Cai, L., Cheng, ZS.,, Cheng, H., Deng, T. ve diğ. (2020). Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM)A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Military Medical Research 7:4. https://pubmed.ncbi.nlm.nih.gov/32029004/
  • Li, T. (2020). Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerging microbes & infections, 9(1), 582–585. https://doi.org/10.1080/22221751.2020.1735265
  • Moore, N. (2020).Chloroquine for COVID‑19 Infection Drug Safety volume 43, pages393–394(2020). https://link.springer.com/article/10.1007/s40264-020-00933-4
  • Rabby., IS. (2020). Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J Pharm Pharm Sci. 2020;23(1):58-64. doi: 10.18433/jpps31002. PMID: 32251618.
  • Sahraei, Z., Shabani, M., Shokouhi, S., & Saffaei, A. (2020). Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International journal of antimicrobial agents, 55(4), 105945. https://doi.org/10.1016/j.ijantimicag.2020.105945
  • Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020). Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome, 14(3), 241–246. https://doi.org/10.1016/j.dsx.2020.03.011
  • Stahlmann, R. ve Lode, H. (2020). Medication for COVID-19-an Overview of Approaches Currently Under Study. Dtsch Arztebl Int. 2020 Mar 27;117(13):213-219. doi: 10.3238/arztebl.2020.0213. PMID: 32343658; PMCID: PMC7196844.
  • Suna, X., Nib, Y., ve Miaojia Zhanga, M. (2020) Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 Emerging Microbes & Infections 2020, VOL. 9. https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1760145
  • Tu, Y.F, Chien, CS., Yarmishyn, AA., Lin, YY., Luo, YH., Lin, YT. Ve diğ. (2020). A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657. PMID: 32290293; PMCID: PMC7177898.
  • Valencia D. N. (2020). Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. Cureus, 12(3), e7386. https://doi.org/10.7759/cureus.7386
  • Yavuz, S ve Ünal, S. (2020). Antiviral treatment of COVID-19 Turkish Journal of Medical Sciences. Turk J Med Sci (2020) 50: 611-619 © TÜBİTAK doi:10.3906/sag-2004-145. https://journals.tubitak.gov.tr/medical/issues/sag-20-50-si-1/sag-50-si-1-18-2004-145.pdf
  • Zhanga, W., Zhaoa, Y., Zhanga, F., Wanga, O., Lib, T., , Liuc,Z. ve diğ. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology 214 (2020) 108393. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102614/

POTENTIAL TREATMENT OPTIONS FOR COVID-19 IN THE EARLY STAGE OF THE PANDEMIC: A RAPID REVIEW

Yıl 2020, Cilt 4, Sayı 2, 36 - 48, 31.12.2020

Öz

Although there is no proven effective treatment against SARS-CoV-2 infection in the early period of the pan-demic, countries apply different treatments according to the severity of health status of patients. In this study, it is aimed to conduct a rapid review of scientific studies on potential drug options that can be used in early treatment of the COVID-19 pandemic. The literature review has been conducted in OVID-Medline, Web of Sci-ence and Dergipark databases in between the dates 01.01.2020-25.04.2020. As a result of the review, a total of 629 study have been accessed and after the assesment being made 25 studies were subject to full text evalua-tion. In the study, as a result we have seen at the early stage of COVID-19 pandemic that there have been no drugs that the efficacy has been yet proved scientifictly. However, we have also seen that there are ongoing clinical trials in order to obtain strong evidence pertaining potential effects of the different kind of medicines and it has also been emphasized that there is a requirement to be cautious in terms of the potential side effects of current drugs. We believe the evidence obtained from the large-scale clinical trials will respond the ongo-ing debates for the effects of these medicines.

Kaynakça

  • Ahn, DG., Shin, HJ., Kim, MH., Lee, S., Kim, HS., Myoung, J., Kim, BT., Kim, SJ. (2020). Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324. doi: 10.4014/jmb.2003.03011. PMID: 32238757
  • Arsene, AL., Ion-Bogdan Dumıtrescu, IB., Drăgoı CM., Udeanu, DI., Lupulıasa, D., Jınga 1V. ve diğ. (2020). A New Era for the Therapeutic Management of the Ongoing COVID-19 Pandemic FARMACIA Vol. 68, 2. https://www.researchgate.net/publication/341036236_A_new_era_for_the_therapeutic_management_of_the_ongoing_COVID-19_pandemic
  • Bebitoğlu, B., Oğuz, E., Hodzic,A., Hatiboğlu, N., Kam, Ö. (2020) Klorokin/Hidroksiklorokin: COVID-19 Tedavisi ile Gündeme Gelen Eski Bir İlaca Farmakolojik Bakış, Anadolu Kliniği Tıp Bilimleri Dergisi, Ocak 2020; Cilt 25, Özel Sayı https://dergipark.org.tr/tr/download/article-file/1115947
  • Borba, MGS. Va,. FFA. Sampaio, VS. Alexandre, MAA., Melo GC, Brito M. ve CloroCovid-19 Team (2020). Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857. PMID: 32330277.
  • Centers for Disease Control and Prevention (2020). Erişim: 18 Mayıs 2020 https://www.cdc.gov/coronavirus/COVID-19/index.html.
  • Chakraborty, C., Sharma, A.R.. Sharma, G, Bhattacharya, M., Lee, S.S.(2020). SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. European Review for Medical and Pharmacological Sciences 2020; 24: 4016-4026. https://pubmed.ncbi.nlm.nih.gov/32329877/
  • Demirbilek, Y., Pehlivantürk, G., Özgüler, ZÖ., Alp Meşe, E., (2020) COVID-19 outbreak control, example of ministry of health of Turkey Turk J Med Sci (2020) 50: 489-494 T https://dergipark.org.tr/tr/pub/tbtkmedical/issue/53865/724486ÜBİTAK doi:10.3906/sag-2004-187.
  • Dong, L., Hu, S., Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012. PMID: 32147628.
  • Dünya Sağlık Örgütü (2020). Erişim: 18 Mayıs 2020. Coronavirus disease (COVID-19) Erişim: 20 Mayıs 2020.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they happen
  • Esposito,S., Noviello, S., Pagliano, P. (2020). Update on treatment of COVID-19:ongoing studies between promising and disappointing results. Le Infezioni in Medicina, n. 2, 198-211, 2020. https://pubmed.ncbi.nlm.nih.gov/32335561/
  • Gautret P, Lagier JC, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020;20:105949. doi: 10.1016/j.ijantimicag. 2020.105949 https://pubmed.ncbi.nlm.nih.gov/32205204/
  • Gao, J.; Tian, Z.; Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends 2020, 14, 72–73) ( Wang, M.; Cao, R.; Zhang, L.; Yang, X.;
  • Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30, 269–271.
  • Gupta, N., Agrawal, S., ve Ish, P. (2020). Chloroquine in COVID-19: the evidence Monaldi Archives for Chest Disease. Monaldi Archives for Chest Disease, Vol. 90 No. 1 (2020) https://covid19.elsevierpure.com/en/publications/chloroquine-in-covid-19-the-evidence
  • Harapana, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Wagner, A. L., & Mudatsir, M. (2020). Coronavirus disease 2019 (COVID-19): A literature review. Journal of infection and public health, 13(5), 667–673. https://doi.org/10.1016/j.jiph.2020.03.019
  • Ingraham, NE., Boulware, D., Sparks, MA., Schacker, T., Benson, B., Sparks, JA. ve diğ. (2020). Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2. Critical Care (2020) 24:182. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187670/
  • Iyer M., Jayaramayya, K., Subramaniam, MD., Lee, SB., Dayem, AA., Cho, SG, Vellingiri, B. 82020). COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep. 2020 Apr;53(4):191-205. doi: 10.5483/BMBRep.2020.53.4.080. PMID: 32336317; PMCID: PMC7196187.
  • Jin, YH., Cai, L., Cheng, ZS.,, Cheng, H., Deng, T. ve diğ. (2020). Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM)A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Military Medical Research 7:4. https://pubmed.ncbi.nlm.nih.gov/32029004/
  • Li, T. (2020). Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerging microbes & infections, 9(1), 582–585. https://doi.org/10.1080/22221751.2020.1735265
  • Moore, N. (2020).Chloroquine for COVID‑19 Infection Drug Safety volume 43, pages393–394(2020). https://link.springer.com/article/10.1007/s40264-020-00933-4
  • Rabby., IS. (2020). Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J Pharm Pharm Sci. 2020;23(1):58-64. doi: 10.18433/jpps31002. PMID: 32251618.
  • Sahraei, Z., Shabani, M., Shokouhi, S., & Saffaei, A. (2020). Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International journal of antimicrobial agents, 55(4), 105945. https://doi.org/10.1016/j.ijantimicag.2020.105945
  • Singh, A. K., Singh, A., Shaikh, A., Singh, R., & Misra, A. (2020). Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & metabolic syndrome, 14(3), 241–246. https://doi.org/10.1016/j.dsx.2020.03.011
  • Stahlmann, R. ve Lode, H. (2020). Medication for COVID-19-an Overview of Approaches Currently Under Study. Dtsch Arztebl Int. 2020 Mar 27;117(13):213-219. doi: 10.3238/arztebl.2020.0213. PMID: 32343658; PMCID: PMC7196844.
  • Suna, X., Nib, Y., ve Miaojia Zhanga, M. (2020) Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 Emerging Microbes & Infections 2020, VOL. 9. https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1760145
  • Tu, Y.F, Chien, CS., Yarmishyn, AA., Lin, YY., Luo, YH., Lin, YT. Ve diğ. (2020). A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657. PMID: 32290293; PMCID: PMC7177898.
  • Valencia D. N. (2020). Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. Cureus, 12(3), e7386. https://doi.org/10.7759/cureus.7386
  • Yavuz, S ve Ünal, S. (2020). Antiviral treatment of COVID-19 Turkish Journal of Medical Sciences. Turk J Med Sci (2020) 50: 611-619 © TÜBİTAK doi:10.3906/sag-2004-145. https://journals.tubitak.gov.tr/medical/issues/sag-20-50-si-1/sag-50-si-1-18-2004-145.pdf
  • Zhanga, W., Zhaoa, Y., Zhanga, F., Wanga, O., Lib, T., , Liuc,Z. ve diğ. (2020). The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology 214 (2020) 108393. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102614/

Ayrıntılar

Birincil Dil Türkçe
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Makaleler
Yazarlar

Elife DİLMAÇ ARTUN> (Sorumlu Yazar)
T.C. Sağlık Bakanlığı
0000-0003-2572-442X
Türkiye


Banu AYAR>
Sağlık Bakanlığı
Türkiye


Gülcan TECİRLİ>
Sağlık Bakanlığı
0000-0001-6244-3753
Türkiye

Destekleyen Kurum Sağlık Bakanlığı
Yayımlanma Tarihi 31 Aralık 2020
Yayınlandığı Sayı Yıl 2020, Cilt 4, Sayı 2

Kaynak Göster

APA Dilmaç Artun, E. , Ayar, B. & Tecirli, G. (2020). PANDEMİNİN ERKEN DÖNEMİNDE COVID-19 İÇİN POTANSİYEL TEDAVİ SEÇENEKLERİ: HIZLI SİSTEMATİK İNCELEME . Eurasian Journal of Health Technology Assessment , 4 (2) , 36-48 . Retrieved from https://dergipark.org.tr/tr/pub/ehta/issue/59458/849832

Açık erişimli ve çift-kör hakemli bir dergidir.

Dergi içeriği tüm kullanıcılara ücretsiz olarak sunulmaktadır.
Dergideki yazıların bilimsel sorumluluğu yazarlarına aittir.
Dergimizde yayınlanmış makaleler kaynak gösterilmeden kullanılamaz
© T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü Araştırma, Geliştirme ve Sağlık Teknolojisi Değerlendirme Dairesi Başkanlığı
Tüm Hakları Türkiye Cumhuriyeti Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğüne aittir.